兽药市场按产品类型、疾病类型、动物类型、配方、给药途径和最终用户划分－2025-2030 年全球预测

兽药市场预计到 2024 年将达到 197.7 亿美元，到 2025 年将达到 208.2 亿美元，到 2030 年将达到 273 亿美元，复合年增长率为 5.52%。

主要市场统计数据
基准年2024年	197.7亿美元
预计2025年	208.2亿美元
预计2030年	273亿美元
复合年增长率（%）	5.52%

为全面了解当前全球兽药市场的动态和关键驱动因素奠定基础

近年来，受全球动物蛋白需求成长、抗菌素抗药性监管要求日益严格以及生产效率日益提升的推动，兽医领域经历了重大变革时期。随着牲畜数量不断扩大以满足消费需求，生产者和兽医都面临着采用先进治疗性介入干预措施的压力，需要在保障动物健康和公共的同时，确保动物健康。此外，药物製剂和给药系统的持续创新正在扩展治疗套件，以应对从细菌感染到寄生虫感染以及代谢紊乱等一系列健康挑战。

重新定义动物健康管理策略，探索推动兽医学创新的关键变革力量

过去十年，超越传统医药创新的变革力量重塑了畜牧医学的模式。精准畜牧技术已成为现代牛健康管理的基石，能够即时监测生理指标和环境条件，从而主动应对健康威胁。同时，数位平台与云端基础分析技术的融合，为兽医和酪农提供了数据主导的决策工具，促进了更有针对性的干预措施和优化的治疗方法。

评估2025年美国关税调整对畜牧药品和贸易的经济和管理影响

美国2025年新关税的实施对整个兽药供应链和定价体系产生了一系列连锁反应。主要活性药物原料药和最终产品进口关税的提高，增加了国内製剂製造商的生产成本，迫使他们探索其他采购途径并重新协商供应商合约。因此，欧洲和亚洲的区域製造地已成为筹资策略的关键枢纽，前置作业时间和物流弹性成为采购团队的核心考量。

多维细分洞察揭示了按产品类型、疾病类型、动物类型、配方和最终用户分類的多样化需求模式

要了解兽药的广度，需要仔细观察需求在多个细分维度上的差异，每个维度都反映了不同的治疗需求和使用情境。就产品类型而言，市场的核心支柱是抗发炎药物、抗生素、抗寄生虫药、饲料添加剂、荷尔蒙和各种疫苗。抗生素包括头孢菌素、青霉素和四环霉素；杀寄生虫药包括体外寄生虫药和体内寄生虫药；同时，饲料添加剂提供各种益生元和益生菌製剂；激素分为生长激素和生殖激素；疫苗技术包括灭活疫苗、减毒活病毒疫苗和次单位疫苗。

美洲、欧洲、中东和非洲地区以及亚太地区兽药应用趋势和市场动态的区域分析

区域动态在塑造畜牧药品组合方面发挥着至关重要的作用，不同的经济和监管环境会影响采用率和治疗重点。北美和南美正越来越多地采用精准医疗方法，并拥有强大的生产系统，这得益于对数位医疗基础设施和先进抗菌药物管理政策的大量投资。跨境贸易协定和区域协调努力正在进一步扩大先进动物用药品的可及性，并创造出以快速产品上市和合作研究倡议为特征的竞争环境。

介绍推动兽药竞争优势和技术进步的先锋产业参与者和策略联盟

在这种竞争格局中，那些对特定行业趋势敏感的公司凭藉强大的研发开发平臺和策略合作伙伴关係脱颖而出，从而增强了其治疗产品组合。全球领先的动物用药品开发商正在利用其在生物技术和数位健康领域的多学科专业知识，开发下一代疫苗、长效製剂和精准给药平台。同时，专业的生物技术企业正专注于抗寄生虫生技药品和微生物饲料改良剂等利基领域，取得进展。

为动物保健产业领导者提供可行的策略建议，提供实现持续成长和市场领导地位的实用途径

为了在不断变化的市场环境中取得成功，行业领导者应优先投资数位医疗基础设施和精准畜牧业解决方案。加强即时监测能力和数据分析框架将有助于更主动地管理疾病，减少治疗方法浪费，并改善动物福利。同时，建立全面的抗菌药物管理计划，纳入疫苗和益生菌等替代疗法，将增强监管合规性和公众信任。

严谨的调查方法，涵盖本报告所依据的资料收集来源、分析架构和检验技术

本报告基于严谨的调查方法，结合二手资料和一手资料，提供全面且可靠的分析。二手资料研究涵盖对科学出版物、政府法规、行业白皮书和公开的企业资料的广泛审查，旨在深入了解市场动态、技术趋势和监管环境。

对引领畜牧业和兽医学发展的相关人员的重要发现和战略意义的摘要

不断变化的法规环境、技术突破和不断变化的消费者期望交织在一起，代表动物保健产业进入了一个充满活力的时代。主要发现包括：数位化医疗解决方案的变革力量、抗菌药物管理的重要性，以及在关税压力日益增加的情况下，供应链多元化的策略需求。此外，深入的細項分析揭示了不同疾病类型、动物类别、配方偏好和最终用户特征对产品和服务的不同需求，凸显了有针对性的商业策略的价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

• 利用新型抗菌肽对抗乳牛抗药性病菌感染
• 整合高精准度牲畜监测感测器，实现即时疾病诊断和治疗
• 开发植物来源免疫刺激剂以减少养猪生产中的抗生素依赖
• 监管改革鼓励在家禽养殖中引入疫苗并加强生物安全措施
• 扩大长效注射驱虫剂配方以提高羊群依从性
• 远端医疗平台的成长，实现了远距兽医咨询和处方笺管理

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第八章兽药市场（依产品类型）

• 抗发炎剂
• 抗生素
  • 头孢菌素类
  • 青霉素
  • 四环霉素
• 抗寄生虫药物
  • 杀外寄生虫剂
  • 体内杀寄生虫剂
• 饲料添加剂
  • 益生元
  • 益生菌
• 荷尔蒙
  • 生长激素
  • 生殖荷尔蒙
• 疫苗
  • 灭活疫苗
  • 减毒活疫苗
  • 次单位疫苗

第九章兽药市场（依疾病类型）

• 感染疾病
• 代谢疾病
• 营养缺乏
• 寄生虫病
• 生殖疾病

第十章兽药市场（依动物类型）

• 水产养殖
• 牛
• 山羊
• 家禽
• 羊
• 猪

第11章兽药市场（按剂型）

• 胶囊
• 凝胶
• 液体
• 粉末
• 药片

第十二章 兽药市场依管理途径划分

• 吸入
• 注射
  • 肌肉注射
  • 静脉
• 口服
  • 液体
  • 药片
• 话题
  • 奶油
  • 修补

第十三章兽药市场（依最终用户）

• 畜牧养殖户
• 兽医诊所
• 兽医诊所

第 14 章：美洲兽药市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

第 15 章：欧洲、中东和非洲兽药市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

第 16 章：亚太兽药市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Anicon Labor GmbH by SAN Group GmbH
  • AniCura Group by Mars Petcare
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Calier Laboratories SA
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Inc.
  • HESTER BIOSCIENCES LIMITED
  • HIPRA SA
  • Indian Immunologicals Ltd.
  • Koninklijke DSM NV
  • Merck KGaA
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Parnell Pharmaceuticals Holdings Ltd.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Vetpharma Animal Health SL
  • Virbac SA
  • Zoetis Inc.

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Livestock Medicine Market was valued at USD 19.77 billion in 2024 and is projected to grow to USD 20.82 billion in 2025, with a CAGR of 5.52%, reaching USD 27.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 19.77 billion
Estimated Year [2025]	USD 20.82 billion
Forecast Year [2030]	USD 27.30 billion
CAGR (%)	5.52%

Setting the Stage for Comprehensive Insights into the Current Dynamics and Key Drivers Shaping Livestock Medicine Markets Globally

In recent years, the livestock medicine sector has undergone a period of remarkable transformation driven by escalating global demand for animal protein, stringent regulatory requirements regarding antimicrobial resistance, and heightened focus on production efficiency. As livestock populations expand to meet consumption needs, producers and veterinarians alike are under mounting pressure to adopt advanced therapeutic interventions that ensure animal health while safeguarding public safety. Moreover, continuous innovation in pharmacological formulations and delivery systems has broadened the therapeutic toolkit available to address a spectrum of health challenges spanning bacterial infections, parasitic infestations, and metabolic disorders.

Moving forward, understanding the confluence of demographic shifts, policy frameworks, and scientific breakthroughs is critical for stakeholders seeking to navigate this dynamic environment. Analysts and decision-makers must consider how emerging disease threats, evolving animal husbandry practices, and sustainability imperatives intersect to shape investment priorities and commercial strategies. By providing a comprehensive overview of current market dynamics and emerging patterns, this executive summary lays the foundation for a deeper exploration of critical industry trends, regulatory influences, and segmentation nuances. Through a structured narrative, readers will gain clarity on the forces accelerating change, the areas of greatest opportunity, and the potential obstacles that may temper growth. This introduction sets the stage for a nuanced examination of transformative shifts, tariff impacts, segmentation insights, and strategic recommendations presented in subsequent sections.

Exploring the Major Transformative Forces Redefining Livestock Health Management Strategies and Driving Innovation Across Veterinary Medicine

Over the past decade, the livestock medicine landscape has been reshaped by a constellation of transformative forces that extend beyond traditional pharmaceutical innovation. Precision livestock farming technologies have emerged as a cornerstone of modern herd health management, enabling real-time monitoring of physiological indicators and environmental conditions to preemptively address health threats. Simultaneously, the integration of digital platforms and cloud-based analytics has empowered veterinarians and farmers with data-driven decision-making tools, fostering more targeted interventions and optimized treatment regimens.

In parallel, growing regulatory scrutiny around antimicrobial resistance has catalyzed the development of alternative therapeutics such as vaccines, probiotics, and novel antiparasitic agents. Breakthroughs in subunit and live attenuated vaccine formulations have significantly reduced the reliance on broad-spectrum antibiotics, while advancements in formulation science have improved bioavailability and compliance through innovative delivery mechanisms. Lastly, increasing consumer awareness of animal welfare and sustainable agriculture practices is driving demand for hormone-free feed additives and environmentally responsible pharmaceuticals, prompting industry stakeholders to redefine their research and development priorities.

Assessing the Cascading Economic and Operational Consequences of 2025 United States Tariff Adjustments on Livestock Pharmacy and Trade

The implementation of new tariff measures in 2025 by the United States has introduced a series of ripple effects throughout the livestock medicine supply chain and pricing structures. Heightened import duties on key active pharmaceutical ingredients and finished products have elevated production costs for domestic formulators, compelling manufacturers to explore alternative sourcing corridors and renegotiated supplier agreements. As a result, regional manufacturing hubs in Europe and Asia are emerging as critical pivot points for procurement strategies, with lead times and logistical resilience becoming central considerations for procurement teams.

Moreover, downstream distributors and veterinary service providers are experiencing compressed margins due to escalated acquisition costs, which in turn has triggered a reassessment of pricing models and inventory management practices. These shifts have also accelerated the exploration of local API production and co-manufacturing partnerships as viable cost-mitigation approaches. Although short-term disruptions have tested the adaptability of established supply chains, they have simultaneously fostered a climate of strategic collaboration between governments, research institutions, and private sector actors aiming to enhance domestic API capabilities and reduce tariff vulnerabilities.

Uncovering Multidimensional Segmentation Insights That Illuminate Varied Demand Patterns by Product Type Disease Type Animal Type Formulation and End User

Understanding the breadth of livestock medicine requires a closer look at how demand diverges across multiple segmentation dimensions, each reflecting distinct therapeutic needs and usage scenarios. From a product type perspective, anti-inflammatory agents, antibiotics, antiparasitic agents, feed additives, hormones, and a diverse array of vaccines serve as the core pillars of the market. Antibiotic offerings span cephalosporins, penicillins, and tetracyclines, while antiparasitic portfolios include both ectoparasiticides and endoparasiticides. Meanwhile, feed additives are enriched with prebiotic and probiotic formulations, hormones are classified into growth and reproductive categories, and vaccine technologies encompass inactivated, live attenuated, and subunit options.

When viewed through the lens of disease type, infectious diseases lead the therapeutic agenda, followed by targeted interventions for metabolic disorders, nutritional deficiencies, parasitic infestations, and reproductive ailments. Animal type segmentation underscores differentiated requirements across aquaculture operations, cattle ranching, goat herding, poultry facilities, sheep farms, and swine production systems. Formulation preferences range from capsules and gels to liquids, powders, and tablets, each tailored to stability and ease of administration. Route of administration insights further nuance treatment selection with inhalation therapies, injectable options subdivided into intramuscular and intravenous formats, oral solutions available as liquids and tablets, and topical applications delivered via creams and patches. Finally, end users such as livestock farmers, veterinary clinics, and veterinary hospitals each exert unique purchasing behaviors and service expectations, driving targeted commercial strategies across the value chain.

Analyzing Regional Variations in Livestock Pharmaceutical Adoption Trends and Market Dynamics Across Americas EMEA and Asia-Pacific Territories

Regional dynamics play a crucial role in shaping livestock medicine portfolios, with divergent economic landscapes and regulatory frameworks dictating adoption rates and therapeutic priorities. In the Americas, robust production systems in North and South regions are increasingly adopting precision medicine approaches, supported by substantial investment in digital health infrastructure and progressive antimicrobial stewardship policies. Cross-border trade agreements and regional harmonization efforts further amplify access to advanced veterinary pharmaceuticals, fostering a competitive environment marked by rapid product launches and collaborative research initiatives.

Across Europe, the Middle East, and Africa, stakeholders navigate a complex tapestry of regulatory requirements, ranging from stringent European Union directives on drug residues to rapidly evolving guidelines in emerging African markets. The push for sustainable livestock practices in Europe is driving demand for organic and residue-free alternatives, while Middle Eastern regions are leveraging public-private partnerships to bolster local manufacturing capabilities. Conversely, Asia-Pacific represents a growth engine fueled by expanding aquaculture and poultry operations, with countries such as China and India spearheading large-scale adoption of vaccines and antiparasitic agents. Evolving infrastructures, increasing veterinary service penetration, and government incentives for biosecurity measures are key factors accelerating market uptake across this diverse region.

Profiling Pioneering Industry Participants and Strategic Alliances Driving Competitive Advantage and Technological Advancement in Livestock Therapeutics

Within this competitive landscape, certain industry participants have distinguished themselves through robust R&D pipelines and strategic collaborations that enhance their therapeutic portfolios. Leading global animal health companies are leveraging cross-disciplinary expertise in biotechnology and digital health to develop next-generation vaccines, long-acting formulations, and precision administration platforms. At the same time, specialized biotech ventures are making inroads by focusing on niche segments such as antiparasitic biologics and microbiome-based feed enhancers.

Strategic alliances between pharmaceutical firms and contract research organizations are accelerating clinical trial execution, regulatory submissions, and post-market surveillance activities. This trend is complemented by partnerships with academic institutions that provide early-stage innovation, ensuring a steady flow of novel compounds and delivery technologies. Additionally, emerging players in regional markets are capitalizing on localized manufacturing advantages and tailored formulations to address endemic disease profiles, thereby carving out differentiated market positions. Collectively, these varied approaches are redefining competitive dynamics and underscoring the importance of agility, innovation, and collaboration in sustaining long-term growth trajectories.

Presenting Actionable Strategic Recommendations to Equip Livestock Health Industry Leaders with Practical Pathways for Sustainable Growth and Market Leadership

To thrive amid evolving market conditions, industry leaders should prioritize investment in digital health infrastructures and precision livestock farming solutions. Enhancing real-time monitoring capabilities and data analytics frameworks will enable more proactive disease management, reduce therapeutic waste, and improve animal welfare outcomes. Simultaneously, establishing comprehensive antimicrobial stewardship programs that incorporate alternative therapies such as vaccines and probiotics will strengthen both regulatory compliance and public trust.

Moreover, diversifying supply chain networks through strategic partnerships with regional manufacturers and contract API producers can mitigate tariff-related risks while enhancing operational resilience. Expanding into high-growth segments, including aquaculture and poultry, requires tailored product development and targeted marketing strategies that address specific disease profiles and end-user requirements. Finally, fostering collaborative research initiatives with academic and governmental agencies will accelerate the advancement of novel therapeutics, drive cost efficiencies in clinical development, and fortify the innovation pipeline for sustained competitive differentiation.

Detailing Rigorous Research Methodology Encompassing Data Collection Sources Analytical Frameworks and Validation Techniques Underpinning the Report

This report is grounded in a rigorous research methodology that synthesizes both secondary and primary data sources to deliver a comprehensive and reliable analysis. Secondary research encompassed an extensive review of scientific publications, government regulations, industry white papers, and publicly available company disclosures to establish foundational insights into market dynamics, technological trends, and regulatory landscapes.

Primary research efforts included structured interviews with senior executives, veterinary practitioners, supply chain managers, and end-user stakeholders, providing firsthand perspectives on current challenges, purchasing behaviors, and innovation priorities. Data validation processes involved cross-referencing reported financials, product launch announcements, and patent filings to ensure consistency and accuracy. Analytical frameworks such as SWOT analysis, PESTLE evaluation, and Porter's Five Forces were applied to contextualize competitive positioning, identify growth drivers and barriers, and project strategic implications without the inclusion of specific market sizing or forecasting figures.

Summarizing Key Findings and Strategic Implications for Stakeholders Navigating the Evolving Landscape of Livestock Medicine and Veterinary Care

The convergence of evolving regulatory environments, technological breakthroughs, and shifting consumer expectations has set the stage for a dynamic era in livestock medicine. Key discoveries include the transformative power of digital health solutions, the critical importance of antimicrobial stewardship, and the strategic necessity of diversified supply chains in the face of tariff pressures. Additionally, in-depth segmentation analyses reveal distinct product and service requirements across disease types, animal categories, formulation preferences, and end-user profiles, underscoring the value of targeted commercial strategies.

As regional markets continue to diverge in terms of regulatory rigor and infrastructural readiness, stakeholders must adopt flexible approaches that balance global best practices with local market realities. By integrating strategic partnerships, embracing innovation-driven collaborations, and reinforcing data-driven decision-making processes, industry participants can position themselves to capitalize on emerging opportunities while navigating potential disruptions. This executive summary has distilled the essential insights necessary to inform strategic planning and guide resource allocation, paving the way for more resilient and responsive operations in the livestock medicine sector.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Adoption of novel antimicrobial peptides to combat resistant bacterial infections in dairy cattle
• 5.2. Integration of precision livestock monitoring sensors for real-time disease diagnostics and medication dosing
• 5.3. Development of plant-based immunostimulants reducing antibiotic dependency in swine production
• 5.4. Regulatory shifts incentivizing vaccine deployment and enhanced biosafety measures in poultry farming
• 5.5. Expansion of long-acting injectable anthelmintic formulations to improve compliance in sheep herds
• 5.6. Growth of telemedicine platforms enabling remote veterinary consultations and prescription management

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Livestock Medicine Market, by Product Type

• 8.1. Introduction
• 8.2. Anti-inflammatory Agents
• 8.3. Antibiotics
  • 8.3.1. Cephalosporins
  • 8.3.2. Penicillins
  • 8.3.3. Tetracyclines
• 8.4. Antiparasitic Agents
  • 8.4.1. Ectoparasiticides
  • 8.4.2. Endoparasiticides
• 8.5. Feed Additives
  • 8.5.1. Prebiotics
  • 8.5.2. Probiotics
• 8.6. Hormones
  • 8.6.1. Growth Hormones
  • 8.6.2. Reproductive Hormones
• 8.7. Vaccines
  • 8.7.1. Inactivated Vaccines
  • 8.7.2. Live Attenuated Vaccines
  • 8.7.3. Subunit Vaccines

9. Livestock Medicine Market, by Disease Type

• 9.1. Introduction
• 9.2. Infectious Diseases
• 9.3. Metabolic Diseases
• 9.4. Nutritional Deficiency Diseases
• 9.5. Parasitic Diseases
• 9.6. Reproductive Diseases

10. Livestock Medicine Market, by Animal Type

• 10.1. Introduction
• 10.2. Aquaculture
• 10.3. Cattle
• 10.4. Goats
• 10.5. Poultry
• 10.6. Sheep
• 10.7. Swine

11. Livestock Medicine Market, by Formulation

• 11.1. Introduction
• 11.2. Capsules
• 11.3. Gels
• 11.4. Liquids
• 11.5. Powders
• 11.6. Tablets

12. Livestock Medicine Market, by Route of Administration

• 12.1. Introduction
• 12.2. Inhalation
• 12.3. Injectable
  • 12.3.1. Intramuscular
  • 12.3.2. Intravenous
• 12.4. Oral
  • 12.4.1. Liquids
  • 12.4.2. Tablets
• 12.5. Topical
  • 12.5.1. Creams
  • 12.5.2. Patches

13. Livestock Medicine Market, by End Users

• 13.1. Introduction
• 13.2. Livestock Farmers
• 13.3. Veterinary Clinics
• 13.4. Veterinary Hospitals

14. Americas Livestock Medicine Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Livestock Medicine Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Livestock Medicine Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Anicon Labor GmbH by SAN Group GmbH
  • 17.3.2. AniCura Group by Mars Petcare
  • 17.3.3. Biogenesis Bago SA
  • 17.3.4. Boehringer Ingelheim International GmbH
  • 17.3.5. Calier Laboratories S.A.
  • 17.3.6. Ceva Sante Animale
  • 17.3.7. Dechra Pharmaceuticals PLC
  • 17.3.8. Elanco Animal Health Inc.
  • 17.3.9. HESTER BIOSCIENCES LIMITED
  • 17.3.10. HIPRA S.A.
  • 17.3.11. Indian Immunologicals Ltd.
  • 17.3.12. Koninklijke DSM N.V.
  • 17.3.13. Merck KGaA
  • 17.3.14. Neogen Corporation
  • 17.3.15. Norbrook Laboratories Ltd.
  • 17.3.16. Parnell Pharmaceuticals Holdings Ltd.
  • 17.3.17. Phibro Animal Health Corporation
  • 17.3.18. Vetoquinol S.A.
  • 17.3.19. Vetpharma Animal Health S.L.
  • 17.3.20. Virbac SA
  • 17.3.21. Zoetis Inc.

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. LIVESTOCK MEDICINE MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. LIVESTOCK MEDICINE MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. LIVESTOCK MEDICINE MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. LIVESTOCK MEDICINE MARKET: RESEARCHAI
• FIGURE 28. LIVESTOCK MEDICINE MARKET: RESEARCHSTATISTICS
• FIGURE 29. LIVESTOCK MEDICINE MARKET: RESEARCHCONTACTS
• FIGURE 30. LIVESTOCK MEDICINE MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. LIVESTOCK MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 95. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 97. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 99. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 101. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
• TABLE 103. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 105. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 107. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 109. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 111. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 113. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 115. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 117. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 119. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 121. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 123. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 125. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 127. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 129. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 131. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 132. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 133. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 134. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 135. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 136. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 137. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 138. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 139. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 140. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 141. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 142. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 143. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 144. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 145. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 146. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 147. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 148. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 149. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 150. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 151. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 152. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 153. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 154. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 155. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 157. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 159. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 161. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 162. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 163. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 164. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 165. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 166. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 167. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 168. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 169. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 170. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 171. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 172. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 173. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 174. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 175. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 176. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 177. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 178. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 179. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 180. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 181. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 182. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 183. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 184. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 185. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 186. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 187. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 188. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 189. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 190. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 191. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 193. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 194. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 195. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 196. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 197. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 198. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 199. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 200. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 201. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 202. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 203. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 204. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 205. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 206. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 207. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 208. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 209. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 210. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 211. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 212. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 213. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 214. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 215. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 216. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 217. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 218. CANADA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 219. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 220. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 221. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 222. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 223. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 224. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 225. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 226. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 227. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 228. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 229. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 230. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 231. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 232. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 233. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 234. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 235. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 236. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 237. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 238. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 239. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 240. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 241. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 242. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 243. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 244. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 245. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 246. MEXICO LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 247. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 248. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 249. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 250. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 251. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 252. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 253. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 254. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 255. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 256. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 257. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 258. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 259. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 260. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 261. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 262. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 263. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 264. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 265. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 266. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 267. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 268. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 269. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 270. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 271. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 272. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 273. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 274. BRAZIL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 275. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 276. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 277. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 278. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 279. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 280. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 281. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 282. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 283. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 284. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 285. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 286. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 287. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 288. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 289. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 290. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 291. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 292. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 293. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 295. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 296. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 297. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 298. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 299. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 300. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 301. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 302. ARGENTINA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2024 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2025-2030 (USD MILLION)
• TABLE 313. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
• TABLE 314. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
• TABLE 315. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
• TABLE 316. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
• TABLE 317. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
• TABLE 318. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
• TABLE 319. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
• TABLE 320. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
• TABLE 321. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 322. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 323. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 324. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2025-2030 (USD MILLION)
• TABLE 325. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 326. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
• TABLE 327. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 328. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
• TABLE 329. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2024 (USD MILLION)
• TABLE 330. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025-2030 (USD MILLION)
• TABLE 331. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 332. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 333. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
• TABLE 334. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
• TABLE 335. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
• TABLE 336. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2025-2030 (USD MILLION)
• TABLE 337. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2024 (USD MILLION)
• TABLE 338. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2025-2030 (USD MILLION)
• TABLE 339. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
• TABLE 340. UNITED KINGDOM LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2025-2030 (USD MILLION)
• TABLE 341. UNITED KINGDOM LIVESTOCK